Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag
MCT’s collaboration with Onxeo on HCC Phase III study in Middle East
Related Posts
-
MCT leads Workshop on "Clinical ...
Read more... -
After more than 10 years of ...
Read more... -
MCT is pleased to communicate about ...
Read more... -
22 MCT team members coming from ...
Read more... -
MCT is looking for Senior Clinical ...
Read more... -
MCT CRA Mariana Alnazer has written ...
Read more... -
MCT is currently involved in 5 ...
Read more... -
MCT will attend Outsourcing in ...
Read more... -
MCT will exhibit at Partnership in ...
Read more... -
Following inspection, MCT local team ...
Read more... -
MCT will organize a Webinar on ...
Read more... -
MCT inaugurates in April 15 it new ...
Read more... -
MCT team meets Tunisian health ...
Read more... -
Interview of Nada Taha, MCT Senior ...
Read more... -
MCT Clinical Project Lead Marwan ...
Read more... -
MCT is grateful to Pr. Olayemi and ...
Read more...